The upper rungs, ranked by evidence
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
Side effects
Page 5 of 21 of this archive, newest first.
A supply gap is a pharmacological event
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
The effect profile, predicted from an expression map
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
Nigeria pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Residual stomach content on endoscopy: the studies
Holding a dose before a procedure has a kinetic problem: a weekly drug with a seven-day half-life cannot be cleared by skipping one injection.
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
India pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Reading the semaglutide titration schedule as a regulatory artefact
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What a month without the drug does to tolerability
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
Sweden pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
The area postrema, and the anatomy of an unwanted effect
Delayed gastric emptying is a mechanism that becomes an adverse effect above a threshold. It is not a complication in the ordinary sense.
The incidence tables, read line by line
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
What the new Sweden guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Portugal pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Australia pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Delayed emptying explains some of this, and not all of it
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Switzerland pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.